Skip to content
You are now leaving to visit

New England Journal of Medicine Publishes Results from Pivotal Study of WAYLIVRA® (volanesorsen) in Patients with Familial Chylomicronemia Syndrome

Mean triglyceride levels decreased 77% in volanesorsen-treated patients versus an 18% increase in patients in placebo group Ionis Logo Akcea launching WAYLIVRA in the European Union BOSTON and CARLSBAD, Calif, Aug. 07, 2019 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc.